Immunome Can Take The Fight To Competitors With Varegacestat
Immunome's varegacestat is in a phase 3 trial in patients with desmoid tumors that should produce results in H2'25. Read why ...
stocknews15h
3 Biotech Stocks Revolutionizing Healthcare
Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.
The drawdown of the big dogs is a correction, not the start of a bear market – GS
The equity market's drop, triggered by DeepSeek’s R1 LLM model news, was a correction and not the start of a sustained bear ...
Ventana Biotech, Inc. (VNTAD) Announces Name Change to Ventana Global, Inc. and Significant Outstanding Share Reduction
"Both the change of name, and outstanding share reduction initiatives mark significant steps forward for the development of Ventana Global, Inc," stated Stephen Replin, President and CEO of the ...